| Cancer Type | PDX/PDOX model ID | CR Cell Line ID | Drug Resistance Patient | Drug Resistance PDX |
|---|---|---|---|---|
| All | LD1-0041-362073 | Imatinib | ||
| All | LD1-1041-362519 | Ibrutinib | ||
| Breast Cancer | LD1-2009-361825 | LD9-2009-361825 | CDK4/6i | |
| Breast Cancer | LD1-2009-361973 | CDK4/6i | ||
| Breast Cancer | LD1-0009-362016 | CDK4/6i | ||
| Breast Cancer | LD1-2009-362153 | CDK4/6i | ||
| Breast Cancer | LD1-0009-362239 | CDK4/6i\Pyrotinib | ||
| Breast Cancer | LD1-2009-362263 | LD9-2009-362263 | ||
| Breast Cancer | LD1-2009-362282 | CDK4/6i | ||
| Breast Cancer | LD1-2009-362310 | CDK4/6i | ||
| Breast Cancer | LD1-0009-362391 | CDK4/6i | ||
| Lung Cancer | LD1-0025-215621 | Gefitinib\Icotinib | ||
| Lung Cancer | LD1-0025-215625 | LD9-0025-215625 | ||
| Lung Cancer | LD1-0025-215648 | LD9-0025-215648 | ||
| Lung Cancer | LD1-0025-215676 | LD9-0025-215676 | Erlotibib | Erlotibib |
| Lung Cancer | LD1-0025-360783 | Erlotibib | ||
| Lung Cancer | LD1-0025-217643 | Gefitinib | ||
| Lung Cancer | LD1-0025-217645 | Gefitinib | ||
| Lung Cancer | LD1-0025-217655 | Erlotinib | ||
| Lung Cancer | LD1-0025-390629 | AZD9291 | ||
| Lung Cancer | LD1-0025-390663 | PD-L1 | ||
| Lung Cancer | LD1-0025-200662 | AZD9291 | Erlotinib\AZD9291 | |
| Lung Cancer | LD1-0025-200694 | LD9-0025-200694 | ||
| Lung Cancer | LD1-0025-200713 | Gefitinib | Erlotinib | |
| Lung Cancer | LD1-0025-200717 | LD9-0025-200717 | Erlotinib\AZD9291 | Erlotinib\AZD9291 |
| Lung Cancer | LD1-0025-200730 | Icotinib\AZD9291\Afatinib | Erlotinib\AZD9291 | |
| Lung Cancer | LD1-0025-200739 | Icotinib | Erlotinib\AZD9291 | |
| Lung Cancer | LD1-0025-200756 | MPDL3280A | ||
| Lung Cancer | LD1-0025-360715 | LD9-0025-360715 | ||
| Lung Cancer | LD1-0025-360764 | LD9-0025-360764 |